Allinaire Therapeutics, a pulmonolgy start up launched by BioMotiv, has recently received new investments from BioCrossroads' Indiana Seed Fund II and Indiana University's Innovate Indiana Fund. The funding will advance the development of therapeutics for the treatment of COPD and other respiratory disorders.
Breathing easy isn't just a euphemism for calming down and taking it easy. It's also the goal of a biotech start-up, Allinaire Therapeutics, which plans to use research from Indiana University School of Medicine to develop new therapies for Chronic Obstructive Pulmonary Disease, or COPD.
BioMotiv, a drug development accelerator associated with the Harrington Project, and Indiana University Research and Technology Corporation, announce the formation of a new biotechnology start-up, Allinaire Therapeutics. Allinaire Therapeutics aims to develop novel therapeutics to fight pulmonary diseases.